摘要
目的:探讨乳腺癌DNA倍体与临床病理因素的关系,进一步研究与乳腺癌发生、发展的关系,预后及治疗上的意义.方法:采用流式细胞技术,对72例乳腺癌组织、69例癌旁组织、74例正常组织进行DNA倍体检测;采用免疫组化SP法检测癌组织激素受体、C-erbB-2.结果:癌组织与癌旁组织及正常组织三组间DNA倍体及异倍体阳性率有显著差异(P<0·01),与C-erbB-2蛋白表达呈正相关(P<0·05),与年龄、肿瘤大小、腋淋巴结转移、激素受体状况无相关性(P>0·05).结论:DNA异倍体可作为对乳腺癌预后的判断指标之一.
Objective:To determine the DNA ploidy in breast cancer and its relation with clinical pathological factors; to further discuss its relation with occurring and progressing of breast cancer and evaluate the significance of DNA ploidy for prognosis and therapy.Methods: The DNA ploidy of 72 breast cancer samples was detected, 69 tissue samples except breast cancer tissues and 74 normal breast tissue samples were detected by flow cytometry (FCM), the levels of estrogen receptor and c-erBb-2 were detected by IHC-SP. Results:Statistical differences of DNA ploidy and positive rate of aneuploidy between the cancer tissue, normal tissue and the tissues except cancer were demonstrated (P<0.01). The protein level of C-erBb-2 was also positively correlated (P<0.05), but no correlation between the ages, size of tumor, axillary lymph nodes and hormone receptor(P>0.05).Conclusion: It is suggested that the detection of expression of DNA aneuploidy may be used to predict the prognosis of patient with breast cancer.
出处
《昆明医学院学报》
2005年第2期89-92,共4页
Journal of Kunming Medical College
